07 March 2006 - DIABETICA ANNOUNCES A DEVELOPMENT LICENCE FOR GIP AGONIST ANTIDIABETIC THERAPEUTICS

Diabetica Limited (Diabetica) (Coleraine, Northern Ireland) today announced a worldwide licensing agreement that provides Amylin Pharmaceuticals, Inc. (Amylin) (San Diego, California) with exclusive rights to Diabetica's intellectual property for the development of GIP Agonists. MORE>>>

07 March 2006 - UUTech CEO WELCOMES DIABETICA WORLDWIDE LICENSING AGREEMENT

Reaction to today's announcement that UU spin-out company Diabetica has signed a worldwide licensing agreement with Amylin Pharmaceuticals, Inc. (Amylin) (San Diego, California) for its groundbreaking diabetes therapy..MORE>>>

Overview

• Diabetes is a major health concern with over 150 million reported cases worldwide and potentially an equal number undiagnosed.

• Diabetica (Diabetica Limited) focuses on innovative research in diabetes therapeutics.

• Strong portfolio of patents and intellectual property exists in six strategic research areas (see below).

Antidiabetic drugs for type 2 diabetes

• To perform cutting edge R&D, providing new products for the control and treatment of diabetes and related illnesses.

• To form successful strategic alliances to capitalize on a growing R&D portfolio of patented discoveries.

• To further expand the infrastructure to enhance the company's research capacity and market potential.

• Bring to market new families of drugs for type 2 diabetes therapy.

• Biomolecules with enhanced potency, duration and spectrum of action.

• Bioengineering human glucose-responsive insulin secreting cells and stem cells.

• Development of pancreatic grafting for treatment of diabetes.

• Exploitation of human insulin secreting cell lines.

• Transplantation and cure of type 1 diabetes.

• Bioactive plants.

• Antihyperglycemic efficacy.

• Potential to treat diabetes and alleviate complications.

• Isolation of bioactive molecules for drug development.

• Pipeline of products for diabetes therapy.

• Isolation of new antidiabetic compounds from natural sources.

• Action mechanisms.

• Therapeutic potential.

• Discovery and development of multi-action products for diabetes therapy.

• Small enzyme-resistant peptides.

• Suppression of appetite

• Weight reduction and improved blood glucose control.

• Products for weight management and treatment of obesity and type 2 diabetes.

• Biomarkers for diabetes, pre-diabetes and blood glucose control.

• Development of biomarkers for diabetes.

• Applications in diagnostic hospital laboratories.

• To perform cutting edge R&D providing new strategies for the treatment of diabetes.

• To capitalize on a growing portfolio of intellectual property and patented discoveries.

• Diabetica Ltd has a pipeline of products at different stages of development in six key areas.

• The opportunity exists to partner with Diabetica to capitalize on existing and future intellectual property in the area of diabetes control and treatment.

• For further information and potential collaboration with Diabetica please contact Matt O'Driscoll (details given below).